ArticleWorld journal of microbiology & biotechnology2025
Efficient fermentative production of SAM through multidimensional engineering of Saccharomyces cerevisiae.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Modification for the Efficient Synthesis of β-ionone by Yarrowia lipolytica.Biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
S-Adenosyl-L-methionine (SAM), an important biochemical substance, is experiencing increased demand due to its versatile applications in the medical field. Although Saccharomyces cerevisiae has been adapted as a promising platform for SAM production, the issue of SAM productivity is still very interesting. In this study, a systematic approach that consists of genome shuffling, genetic engineering, and fermentation process optimization strategies was established. Firstly, haploids of mutant T11-1 and P15-33 were prepared and treated with ultraviolet irradiation (UV) and atmospheric and room temperature plasma (ARTP) compound mutagenesis, which aids to increase SAM production to 1.25, 1.34 g/L, respectively. Genome shuffling was performed with cycloheximide-resistant protoplast of mutant T5-8-1 and hygromycin B-resistant protoplasts of mutant P4-2-4. The resulting fusant TRP60, with a SAM titer of 1.36 g/L, was subjected to transcriptome analysis. Subsequently, hemoglobin from vitreoscilla has been introduced into fusant TRP60 to increase ATP supply and then strengthening the synthesis pathway of SAM, which significantly elevated SAM titer to 2.06 g/L. Finally, the SAM titer of fusant TRP60-vgb-SAM2 reached 14.22 g/L in a 5 L bioreactor with an optimized fed-batch fermentation. Therefore, fusant TRP60-vgb-SAM2 may serve as a candidate for industrial production of SAM.
Indexed as
Identifiers
40999103What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.